Bioverativ Inc. (BIVV) EPS Estimated At $0.48; Sandridge Mississippian Trust II Has 0.33 Sentiment

January 17, 2018 - By Nellie Frank

SandRidge Mississippian Trust II, a statutory trust, holds royalty interests in specified oil and natural gas properties. The company has market cap of $50.22 million. The Company’s properties are located in the Mississippian formation in Alfalfa, Grant, Kay, Noble, and Woods counties in northern Oklahoma and Barber, Comanche, Harper, and Sumner counties in southern Kansas. It has a 4.9 P/E ratio. As of December 31, 2016, the companyÂ’s properties consisted of royalty interests in initial wells and 173 additional wells.

Analysts expect Bioverativ Inc. (NASDAQ:BIVV) to report $0.48 EPS on January, 25.BIVV’s profit would be $51.94 million giving it 33.27 P/E if the $0.48 EPS is correct. After having $0.63 EPS previously, Bioverativ Inc.’s analysts see -23.81% EPS growth. The stock increased 0.19% or $0.12 during the last trading session, reaching $63.87. About 893,706 shares traded. Bioverativ Inc. (NASDAQ:BIVV) has 0.00% since January 17, 2017 and is . It has underperformed by 16.70% the S&P500.

Bioverativ Inc., a biotechnology company, focuses on the research, discovery, development, and commercialization of therapies for the treatment of hemophilia and other blood disorders in the United States and Japan. The company has market cap of $6.91 billion. The firm offers ELOCTATE, an antihemophilic factor Fc fusion protein; and ALPROLIX, a coagulation factor IX (Recombinant) Fc fusion protein for the treatment of hemophilia A and B. It has a 15.59 P/E ratio. It is also developing BIVV 001 (rFVIIIFc-VWF-XTEN), a preclinical program of the combination of factor VIII-Fc fusion protein for the treatment of hemophilia A; BIVV 002 (rFIXFc-XTEN), a preclinical program for a recombinant factor IX replacement product for the treatment of patients with hemophilia B; and Bi-Specific antibody program, a preclinical program to develop a non-factor bi-specific antibody for the treatment of patients with hemophilia A.

Among 2 analysts covering Bioverativ (NASDAQ:BIVV), 1 have Buy rating, 1 Sell and 0 Hold. Therefore 50% are positive. Bioverativ had 2 analyst reports since February 2, 2017 according to SRatingsIntel. The firm has “Buy” rating by Gabelli given on Thursday, February 2. The rating was initiated by Morgan Stanley on Thursday, February 2 with “Underweight”.

California Public Employees Retirement System holds 0% of its portfolio in Sandridge Mississippian Trust II for 129,500 shares. Group One Trading L.P. owns 10,000 shares or 0% of their US portfolio. Moreover, Jpmorgan Chase & Co has 0% invested in the company for 9,100 shares. The New York-based Morgan Stanley has invested 0% in the stock. Raymond James & Associates, a Florida-based fund reported 16,736 shares.

The stock 0.01% or $0 during the last trading session, reaching $1.01. It is up 2.10% since January 17, 2017 and is downtrending. It has underperformed by 18.80% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.